Skip to main content
Search form
Search
Subscribe to newsletter +
European Association of Hospital Pharmacists
Menu
Main menu
Home
About Us
Who we are
Board
Staff
Students
Transparency
Contact Information
Call for Expressions of Interest
Members
Associate membership
News
Press Releases
EAHP Newsletters
EAHP in the news
Multimedia Gallery
Events
Calendar
Academy
Synergy Masterclass
EAHP BOOST
Congresses
General Assemblies
Accreditations
EAHP Synergy Certification Courses
Open Learning
Get Involved
Sponsors and partners
HP Practice
EAHP COVID-19 Resource Centre
European Statements of Hospital Pharmacy
What hospital pharmacists do
EAHP-ESCP Oath to Society
FIP global statements
National legislation on hospital pharmacy
Good Practice Initiatives
Common training framework
Environmental Sustainability
European Council for Pharmacy Education Accreditation
Investigation of the hospital pharmacy profession in Europe
Hospital Pharmacy Day
SIGs
Controlled Substances Management
Special Interest Group on Investigation of medication errors and efficiency in oncology
Automated Medication Management
Working Towards Eliminating Avoidable Harm
Hazardous Medicinal Products
Hospital Pharmacist’s Preparedness for in-vivo gene therapy medicinal products
Investigation of Medication Errors in Intensive Care Units
Use of Prefilled Syringes in Intensive Care Units and Operating Theaters
Policy
Resources
Consultations
Position Papers
Get involved and keep up to date
Access to Medicines
Ageing society
Infectious Diseases and AMR
ATMPs
Bar coding medicines to the single unit
Biosimilar medicines
Clinical trials
Digital Health
EMA - EAHP collaboration
European List of Emergency Medicines
Falsified Medicines
Hazardous Medicinal Products
Hospital Pharmacy Specialisation
Medical device regulation
Medicines shortages
Patient safety
Pharmaceuticals in the environment
Pharmacy preparations and compounding
Procurement
Public spending austerity
SmPC
Vaccination
Workforce
Statements
GPIs
Publications
2019 EP Election Manifesto
General information
EAHP Annual report
European Journals of Hospital Pharmacy
EAHP Surveys of HP practice
EAHP History Book
Practical Pharmaceutics
Congress presentation webcasts
2024 European Parliament Election Manifesto
Member Center
You are here
Home
Section 1: Introductory Statements and Governance
1ISG-013
ECONOMIC IMPACT OF ORPHAN DRUGS USED IN PAEDIATRIC PATIENTS ATTENDING HOSPITAL OUTPATIENT PHARMACY AND DAY HOSPITAL
1ISG-012
THE ROLE OF THE PHARMACIST IN CHOOSING THE CENTRAL VENOUS ACCESS DEVICE FOR THE PREVENTION OF COMPLICATIONS: AN EXAMPLE OF BUDGET IMPACT ANALYSIS
1ISG-007
BIOSIMILAR OF INFLIXIMAB: DOES THE PENETRATION RATE MEET EXPECTATIONS? APPRAISAL IN A CENTRAL PURCHASING OFFICE
1ISG-006
CONTAMINATION OF THE BLISTER PACKS BY POMALIDOMIDE AFTER USE IN CLINICAL SITUATION
1ISG-020
MARKET ACCESS IN THE EU, DO WE HAVE ENOUGH EVIDENCE?
1ISG-009
ECONOMIC IMPACT OF AFLIBERCEPT OPTIMISATION FOR THE TREATMENT OF EYE-RELATED CONDITIONS
1ISG-003
COST SAVING IN ANTIRETROVIRAL THERAPY THROUGH BREAKING FIXED-DOSE COMBINATION AND SWITCH TO GENERIC FORMULATIONS
1ISG-002
EFFECTIVENESS OF ANGIOTENSIN RECEPTOR BLOCKER IN HOSPITALISED PATIENT
1ISG-014
ISO 9001 CERTIFICATION: CUSTOMER FOCUS
1ISG-011
DEVELOPMENT OF A PREDICTIVE MODEL FOR ESTIMATING FUTURE DRUG EXPENSES
1ISG-008
ECONOMIC IMPACT OF THE USE OF BIOSIMILAR INFLIXIMAB IN A SECOND-LEVEL HOSPITAL
1ISG-005
A COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB VERSUS DOCETAXEL FOR ADVANCED NONSQUAMOUS NON-SMALL-CELL LUNG CANCER IN SECOND LINE IN A HEALTHCARE SETTING
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
Follow Us